Efficacy of Preservative-free Latanoprost in Normal-tension Glaucoma with Mild to Moderate Dry Eye

Purpose: We aim to evaluate the impact of combining a preservative-free drop, cyclosporine 0.05% emulsion, and omega-3 oral supplementation on the signs and symptoms of dry eye in a typical ophthalmic practice.Design: A retrospective case series conducted on patients with dry eye disease.Methods: Patients diagnosed with dry eye in a typical ophthalmology practice were initiated on a fixed combination regimen which included a preservative-free eye drop (I-DROP ® PUR GEL, I-MED pharma), cyclosporine 0.05% ophthalmic emulsion, and oral omega-3 supplement(Dry Eye Omega Benefits®, PRN)for 3 monthsconsecutively. The primary outcome measured was a symptom score using the Canadian Dry Eye Assessment Tool (CDEA). Secondary outcome measure was Non-invasive Keratograph Break-up Time (NIKBUT). Primary and secondary outcomes measured at baseline and 3 months following intervention were compared.Results: Thirty-six patients were included with a female male ratio of 2.6:1 and average age of 64.Patient symptoms improved significantly following the intervention as demonstrated by a lower CDEA score during the second visit compared to the first visit (16.11 vs. 19.50, respectively) (p< .05). NIKBUT scores were also significantly improved as demonstrated by a higher score during the second visit compared to the first in both the right (13.18 vs. 11.44) (p< .05) and left (14.62 vs. 12.78) (p< .01) eyes, respectively.Conclusion: A fixed combination of preservative-free eye drops, cyclosporine 0.05% and omega-3 supplementation may be an effective first line treatment option in alleviating symptoms and improving signs of patients suffering from dry eye.

Download Full-text

Analysis of treatment results in dry eye syndrome patients after phacoemulsification by preservative-free 0.3% sodium hyaluronate eye drops

Ophthalmology journal ◽

10.17816/ov10273-77 ◽

2017 ◽

Vol 10 (2) ◽

pp. 73-77

Author(s):

Yury I Pirogov ◽

Galina M Butina ◽

Aleksandr A Oksentjuk ◽

Ekaterina S Khromova

Keyword(s):

Dry Eye ◽

Sodium Hyaluronate ◽

Dry Eye Syndrome ◽

Surgical Trauma ◽

Eye Drops ◽

Mean Values ◽

Tear Secretion ◽

Mild Degree ◽

Patient Symptom ◽

Preservative Free

Postsurgical dry eye syndrome is found in a substantial proportion of patients after phacoemulsification. Its onset could be explained by surgical trauma and by use of preservative-containing eye drops. In some patients, it causes substantial discomfort that continues unabated after 3-4 weeks after surgery. Purpose. To investigate the results of 0.3% sodium hyaluronate instillation therapy used to treat dry eye syndrome after phacoemulsification. Materials and methods. Basal tear secretion (Schirmer II test) and tear breakup time (TBUT) test were investigated in 33 patients with symptoms characteristic of dry eye syndrome in 1 month after phacoemulsification. These patients received 0.3% preservative-free sodium hyaluronate instillations for 30 days, whereupon Schirmer II and TBUT tests were repeated. Symptom dynamics was estimated according to the OSDI questionnaire scale. Results. Mean values of basal tear secretion and TBUT tests were slightly below normal ones. In one month of treatment, the TBUT index associated with “Gilan Ultra Comfort” use became somewhat better: mean TBUT value appeared to be 9.8 ± 2.5 sec. OSDI questionnaire patient symptom score evaluation also revealed in patients a mild degree of xerosis severity. Mean score before treatment was 19.6 ± 10.0. Positive disease dynamics after “Gilan Ultra Comfort” use is confirmed by a significant decrease of OSDI score index up to 12.3 ± 6.3.

Download Full-text

A Retrospective Data Review Confirms That Topical Preservative-Free Hydrocortisone Improves Inflammation in Dry Eye Disease

Clinical Ophthalmology ◽

10.2147/opth.s283655 ◽

2020 ◽

Vol Volume 14 ◽

pp. 3691-3697

Author(s):

Biljana Kuzmanović Elabjer ◽

Leon Marković ◽

Mirjana Bjeloš ◽

Mladen Bušić ◽

Daliborka Miletić ◽

...

Keyword(s):

Dry Eye ◽

Dry Eye Disease ◽

Eye Disease ◽

Retrospective Data ◽

Preservative Free

Download Full-text

Effect of Preservative-free Low-dose Hyaluronic Acid-containing Salt Solution on Dry Eye Disease

Case Medical Research ◽

10.31525/ct1-nct03888183 ◽

2019 ◽

Author(s):

Keyword(s):

Hyaluronic Acid ◽

Dry Eye ◽

Salt Solution ◽

Low Dose ◽

Dry Eye Disease ◽

Eye Disease ◽

Preservative Free

Download Full-text

The effect of preservative-free HP-Guar on dry eye after phacoemulsification: a flow cytometric study

Eye ◽

10.1038/eye.2010.24 ◽

2010 ◽

Vol 24 (8) ◽

pp. 1331-1337 ◽

Cited By ~ 36

Author(s):

M A Sánchez ◽

P Arriola-Villalobos ◽

P Torralbo-Jiménez ◽

N Girón ◽

B de la Heras ◽

...

Keyword(s):

Dry Eye ◽

Flow Cytometric ◽

Flow Cytometric Study ◽

Preservative Free

Download Full-text

Successfully Improving Ocular Drug Delivery Using the Cationic Nanoemulsion, Novasorb

Journal of Drug Delivery ◽

10.1155/2012/604204 ◽

2012 ◽

Vol 2012 ◽

pp. 1-16 ◽

Cited By ~ 103

Author(s):

Frederic Lallemand ◽

Philippe Daull ◽

Simon Benita ◽

Ronald Buggage ◽

Jean-Sebastien Garrigue

Keyword(s):

Clinical Trials ◽

Dry Eye ◽

Ocular Surface ◽

Surface Damage ◽

Symptomatic Treatment ◽

Pharmacokinetic Studies ◽

Beneficial Effects ◽

Ophthalmic Delivery ◽

Preservative Free ◽

Selection Of

Topical ophthalmic delivery of active ingredients can be achieved using cationic nanoemulsions. In the last decade, Novagali Pharma has successfully developed and marketed Novasorb, an advanced pharmaceutical technology for the treatment of ophthalmic diseases. This paper describes the main steps in the development of cationic nanoemulsions from formulation to evaluation in clinical trials. A major challenge of the formulation work was the selection of a cationic agent with an acceptable safety profile that would ensure a sufficient ocular surface retention time. Then, toxicity and pharmacokinetic studies were performed showing that the cationic emulsions were safe and well tolerated. Even in the absence of an active ingredient, cationic emulsions were observed in preclinical studies to have an inherent benefit on the ocular surface. Moreover, clinical trials demonstrated the efficacy and safety of cationic emulsions loaded with cyclosporine A in patients with dry eye disease. Ongoing studies evaluating latanoprost emulsion in patients with ocular surface disease and glaucoma suggest that the beneficial effects on reducing ocular surface damage may also extend to this patient population. The culmination of these efforts has been the marketing of Cationorm, a preservative-free cationic emulsion indicated for the symptomatic treatment of dry eye.

Download Full-text